Adebrelimab with chemo and radiation for high-risk nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy and radiation for people with a high-risk type of nasopharyngeal cancer (stage IVA). The goal is to see if this combination helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer confirmed by biopsy.
- Your cancer is stage IVA (specifically T3N2M0).
- You are between 18 and 65 years old.
- You are generally well enough to be up and about (ECOG score 0 or 1).
- You have adequate blood cell counts and kidney/liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy drugs (GP) plus an immunotherapy drug (adebrelimab) before standard treatment for nasopharyngeal cancer. It aims to see if this combination works better than chemotherapy alone for shrinking tumors.
This trial tests whether adding sintilimab (an immune treatment) to standard chemoradiotherapy can improve outcomes for people with high-risk, locally advanced nasopharyngeal (throat) cancer. It may help your immune system work better against the cancer alongside radiation and chemotherapy.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests whether adding chemotherapy before the usual radiation and chemotherapy treatment can improve outcomes for people with a certain type of nasopharyngeal cancer that has higher risk features. It aims to see if the extra treatment helps control the cancer better.
This trial tests whether adding the immunotherapy drug toripalimab to the chemotherapy pill capecitabine after standard treatment helps prevent nasopharyngeal cancer from coming back. It is for people with high-risk features who have already had chemo and radiation.
This Phase 3 trial studies whether adding low-dose radiation to cadonilimab (an immune therapy) can improve outcomes for people newly diagnosed with a specific type and stage of nasopharyngeal cancer. If you’re eligible, it may offer a new treatment approach and helps researchers confirm whether it works best.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.